Innovent Biologics Reports H1 Net Profit of RMB 1.253 Billion, Up 50.2% YoY
Nashnova编辑部
Innovent Biologics reported H1 net profit of RMB 1.253 billion, up 50.2% year-on-year, as product revenue growth far outpaced total revenue — commercialization is converting into earnings at an accelerating pace.
What do the headline numbers say?
Total revenue hit RMB 8.618 billion, up 44.8% YoY; net profit reached RMB 1.253 billion, up 50.2%.
Profit grew faster than revenue. This means → the company is not just selling more — it is selling more efficiently.
Non-IFRS net profit — stripping out share-based compensation and other non-recurring items — came in at RMB 1.704 billion, up 40.5%, driven by volume ramp and improving operating leverage.
Why did product revenue outrun total revenue?
H1 product revenue was RMB 8.202 billion, up 56.7% — well above the 44.8% growth in total revenue.
In plain terms = total revenue includes licensing fees and other non-product items; the drugs themselves are selling even faster, showing the company's own commercial engine is accelerating.
This reflects a portfolio that has moved past the channel-building phase and into full-scale volume harvesting.
Twenty approved products — how broad is the base?
Innovent now has 20 approved products spanning oncology, autoimmune diseases, and metabolic disorders.
13 of those are listed on the National Reimbursement Drug List (NRDL) — a 65% inclusion rate.
This means → more than six in ten products carry state insurance coverage, lowering the barrier to volume uptake; newly reimbursed oncology drugs ramping up were a core driver of this period's results.
"The best window since founding" — what is the company betting on?
Management called the current moment "the best development window since the company was founded" and laid out a third strategic transformation.
The target: evolve over the next five to ten years from a leading domestic biopharma into a globally capable, world-class biologics company.
Multiple international partnerships landed in H1, but whether that globalization push converts into quantifiable revenue in H2 will be the market's key watch point.
Content is for reference only, not financial advice.